Andere Sprachen MaxCyte, Inc.

Aktien

A2AGVE

US57777K1060

MXCT

Verzögert London S.E. Andere Börsenplätze 13:32:26 19.04.2024			% 5 Tage	% 1. Jan.
312 ^GBX	-0,32 %		-5,45 %	-11,49 %

02.04.	MaxCyte schließt Deal mit Be Bio ab; Orcadian Unternehmen Farmout	AN
02.04.	MaxCyte, Inc. unterzeichnet strategische Plattformlizenz mit Be Biopharma zur Unterstützung der Entwicklung von B-Zell-Medikamenten	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024	10.04.
MaxCyte, Inc. - Exercise of options and PDMR dealing	03.04.
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B cell Medicines	03.04.
MaxCyte inks deal with Be Bio; Orcadian firms farmout	02.04.
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)	02.04.
MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	02.04.
MaxCyte, Inc. - Grant of Options, RSUs and PSUs and PDMR Dealing	21.03.
MaxCyte loss widens in 2023 as core revenue declines 25%	13.03.
North American Morning Briefing : Stock Futures Flat After S&P 500 Hit Record High	13.03.
MaxCyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
Earnings Flash (MXCT) MAXCYTE Reports Q4 Revenue $15.7M, vs. Street Est of $15.1M	12.03.
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance	12.03.
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024	12.03.
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	06.03.
EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit	05.03.
MaxCyte Reaffirms Fiscal 2023 Revenue Guidance	04.03.
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	04.03.
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024	04.03.
MaxCyte, Inc. - Exercise of options and PDMR dealing	01.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MaxCyte, Inc.

Aktien

A2AGVE

US57777K1060

MXCT

Andere Sprachen

Filter